First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
about
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesPhase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancerPreclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.An overview of early investigational therapies for chemoresistant ovarian cancer.Marinopyrroles: Unique Drug Discoveries Based on Marine Natural Products.Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsLurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.An overview of recent advances in duplex DNA recognition by small molecules.Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
P2860
Q26749280-46799740-C7AA-4D7E-8506-16A08B828AFFQ33749044-2255979F-60E9-440B-957D-B868C29F1A3FQ35960779-8390F2CB-4CD3-44D3-BFEB-E4B3C6394EA3Q37295535-297FC894-70D0-4540-AC54-9BB5150AA75CQ38553247-51ECDE9F-0664-41C8-815A-CBCEAB8FFA2FQ38579139-9AE91CC1-99C7-4035-9239-6F5458219D5DQ39010913-2C2A29F2-7626-4148-AA57-492A5B938039Q41524895-9D9F5C59-0274-4098-A335-875FA462F568Q43586163-C4119A78-03BA-40A5-9ACA-63669D3593B0Q50213474-637B35E0-D5C1-44F8-B73C-A73D0DA10709Q52812855-D31D7401-F96C-42B0-83CF-E919B3B0AC86Q53724234-C4156F62-86B3-4D9B-978D-536D22187F12Q55476273-3B6A3778-473E-452C-859D-B56F42E6B1E0Q58702635-272691DE-1D8A-4EF4-BE04-23F7AD1B6222
P2860
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
First-in-human phase I study o ...... ts with advanced solid tumors.
@ast
First-in-human phase I study o ...... ts with advanced solid tumors.
@en
type
label
First-in-human phase I study o ...... ts with advanced solid tumors.
@ast
First-in-human phase I study o ...... ts with advanced solid tumors.
@en
prefLabel
First-in-human phase I study o ...... ts with advanced solid tumors.
@ast
First-in-human phase I study o ...... ts with advanced solid tumors.
@en
P2093
P1476
First-in-human phase I study o ...... ts with advanced solid tumors.
@en
P2093
Arturo Soto-Matos Pita
Carlos Fernandez Teruel
Carmen Kahatt
David Geary
Mariano Siguero
Martin Cullell-Young
María Elena Elez
S Peter Kang
Sergio Szyldergemajn
Teresa Macarulla
P304
P356
10.1158/1078-0432.CCR-13-1880
P407
P577
2014-02-21T00:00:00Z